Genetic Analysis and Eurofins offer standardised GA-map test

Genetic Analysis has announced a Service Agreement with Eurofins ADME Bioanalysis, a CRO who have launched a standardised gut microbiome test (GA-map Dysbiosis Test). 

Gut microbiome profiling is required as a surrogate endpoint or exploratory biomarker in clinical trials. This is due to both the impact new pharmaceuticals can have on microbiomes and the fact that the microbiota composition itself may greatly affect the response to treatment.  

Genetic Analysis profiles and compares an imbalanced microbiota to healthy references. The standardised GA-map Test is based on a pre-determined targets approach (PDT) and is a tool in drug development, clinical research and routine diagnostics. 

Ronny Hermansen, CEO of Genetic Analysis, said: “Genetic Analysis is proud to have Eurofins ADME Bioanalysis as a partner in the clinical research field. To map and unlock the bacteria present in the gut is instrumental for developing better treatment regimes. The GA-map platform will offer a fast turnaround lab testing service with an integrated software algorithm for immediate result presentation.” 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free